BetaSorb™ is designed as an adjunctive treatment to traditional high-flux hemodialysis for the treatment of chronic kidney failure. The National Institutes of Health estimates that Medicare spends $19 billion annually (6% of Medicare expenditures) for the care of 450,000 patients with end-stage kidney failure. The National Kidney Foundation estimates that 20 million people in the U.S. suffer from chronic kidney disease (CKD), a condition in which the kidneys fail to fully perform their normal functions including:
• Regulating body water and chemicals such as sodium, potassium, phosphorous, and calcium
• Removing drugs and toxins introduced into the body
• Releasing hormones into the body in order to regulate blood pressure,
produce red blood cells, and promote strong bones.
The BetaSorb™ technology targets middle molecular weight toxins not cleared well by hemodialysis. The marker is Beta2Microglobulin (β2M). Studies show that reduced levels of β2M lead to a reduction in morbidities like amyloidosis, hospital stays, and lowers mortality rates compared to patients on high-flux hemodialysis.